Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX

Trial Profile

A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexastimogene devacirepvec (Primary) ; Cyclophosphamide
  • Indications Advanced breast cancer; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms METROmaJX
  • Most Recent Events

    • 19 Sep 2018 According to a Transgene media release, At the interim analysis of the patients treated for soft tissue sarcoma, the pre-specified primary endpoint was not reached; enrolment for this indication has been discontinued.
    • 19 Sep 2018 Primary endpoint (Advanced soft-tissue sarcoma: Assessment of the antitumor activity of the association of JX-594 and metronomic cyclophosphamide based on 6 month non-progression (CR, PR or SD more than 24 weeks) following RECIST v1.1 criteria) has not been met, according to a Transgene media release.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top